phase III POSEIDON trial

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

phase III POSEIDON trial

Oct 16, 2024, 12:05 | Insight

Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer

Study finds patients with advanced non-small cell lung cancer and STK11 and/or KEAP1 mutations had…

Oct 11, 2024, 19:32 | Insight

Hung Trinh: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Hung Trinh shared a post on LinkedIn: “CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.…

All: 2 Posts: 1 - 100

'

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

'

Where to Study to Become ASCO President: 2025 Institutional Rankings

'

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

'

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

'

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023